InvestorsHub Logo
Followers 76
Posts 30354
Boards Moderated 85
Alias Born 03/22/2005

Re: None

Tuesday, 02/21/2023 5:57:42 PM

Tuesday, February 21, 2023 5:57:42 PM

Post# of 447
Johnson & Johnson - >>> Johnson & Johnson is a healthcare giant that derives the majority of its growth from its pharmaceutical business. J&J boasts a large product lineup that includes immunology drugs Stelara and Tremfya and cancer drugs Darzalex and Erleada.

The company’s pipeline features more than 50 late-stage clinical testing programs. These clinical trials are testing new drug candidates and seeking additional approvals for drugs such as Darzalex and Imbruvica, which treat cancer.

Johnson & Johnson plans to spin off its consumer health unit into a standalone entity in 2023. This will leave the company with its two fastest-growing segments -- pharmaceutical and medical devices.

J&J ranks as a Dividend King, having raised its annual dividend for 59 consecutive years. Investors don’t have to worry about the dividend with the spinoff of the company’s consumer health business, though. J&J expects that its dividend, combined with the anticipated dividend from the new entity, will remain at least at the same level as before the transaction completes.



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.